Department of Internal Medicine, Virginia Commonwealth University School of Medicine, South Hill, VA, USA.
Lumbini Medical College, Lumbini, Palpa, 32500, Nepal.
F1000Res. 2021 Feb 17;10:124. doi: 10.12688/f1000research.51094.1. eCollection 2021.
Neuroleptic malignant syndrome (NMS) is a well-recognized neurologic emergency. It presents with classic features including hyperthermia, autonomic instability, muscle hypertonia, and mental status changes. The syndrome is potentially fatal and is associated with significant morbidity due to complications such as rhabdomyolysis, acute kidney injury, and ventricular arrhythmias due to the trans-cellular electrolyte shift. NMS is conventionally associated with the first-generation antipsychotic agents, however, has been described with the use of atypical and novel antipsychotics including Ziprasidone. A case of NMS with Ziprasidone use at the therapeutic dose is reported here.
神经阻滞剂恶性综合征(NMS)是一种公认的神经急症。它表现为典型特征,包括高热、自主神经不稳定、肌肉强直和精神状态改变。该综合征具有潜在致命性,并因横纹肌溶解、急性肾损伤和细胞间电解质转移引起的室性心律失常等并发症而导致严重发病率。NMS 通常与第一代抗精神病药物相关,但也已在使用非典型和新型抗精神病药物,包括齐拉西酮时被描述。本文报告了一例在治疗剂量下使用齐拉西酮的 NMS 病例。